Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 11/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536952 | 0.86 | MAPK8 (0.45) | TRPA1METMAPTRXFP1MAPK14 | |
| SCHEMBL25226268 | 0.86 | MAPK8 (0.45) | TRPA1METMAPTRXFP1MAPK14 | |
| SCHEMBL21931437 | 0.86 | MAPT (0.44) | TRPA1L3MBTL1MAPTMAPK14BRD4 | |
| SCHEMBL25043087 | 0.85 | TRPA1 (0.43) | TRPA1METL3MBTL1MAPK14BRD4 | |
| SCHEMBL16650836 | 0.84 | MET (0.44) | TRPA1METL3MBTL1MAPTRXFP1 | |
| SCHEMBL19931198 | 0.82 | TRPA1 (0.40) | TRPA1L3MBTL1MAPK14BRD4HSPB1 | |
| SCHEMBL7666802 | 0.77 | TRPA1 (0.44) | TRPA1MAPK14HSPB1 | |
| SCHEMBL16650461 | 0.76 | BRD4 (0.57) | TRPA1L3MBTL1MAPK14BRD4 | |
| SCHEMBL5912785 | 0.76 | MAPT (0.40) | L3MBTL1MAPTRXFP1 | |
| SCHEMBL14014291 | 0.76 | MAPK8 (0.45) | TRPA1METMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3640241-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-108558889-B | Bromodomain inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2021-11-05 | — | — | CN | disclosed |
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | TRPA1 4826/4885MET 2348/4885L3MBTL1 1519/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | TRPA1 4826/4885MET 2348/4885L3MBTL1 1519/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | TRPA1 4826/4885MET 2348/4885L3MBTL1 1519/4885 |
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | TRPA1 4826/4885MET 2348/4885L3MBTL1 1519/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | TRPA1 4826/4885MET 2348/4885L3MBTL1 1519/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | TRPA1 4826/4885MET 2348/4885L3MBTL1 1519/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | TRPA1 4826/4885MET 2348/4885L3MBTL1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.